Clinical endpoints and adaptive clinical trials in precirrhotic nonalcoholic steatohepatitis: Facilitating development approaches for an emerging epidemic

Claudia Filozof, Shein‐Chung Chow, Lara Dimick‐Santos, Yeh‐Fong Chen, Richard N. Williams, Barry J. Goldstein, Arun Sanyal – 1 August 2017 – Due to the increasing prevalence of nonalcoholic steatohepatitis (NASH) and its associated health burden, there is a high need to develop therapeutic strategies for patients with this disease. Unfortunately, its long and asymptomatic natural history, the uncertainties about disease progression, the fact that most patients are undiagnosed, and the requirement for sequential liver biopsies create substantial challenges for clinical development.

The selective peroxisome proliferator–activated receptor‐delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice

Fahrettin Haczeyni, Hans Wang, Vanessa Barn, Auvro R. Mridha, Matthew M. Yeh, W. Geoffrey Haigh, George N. Ioannou, Yun‐Jung Choi, Charles A. McWherter, Narcissus C.‐H. Teoh, Geoffrey C. Farrell – 31 July 2017 – Lipotoxicity associated with insulin resistance is central to nonalcoholic steatohepatitis (NASH) pathogenesis. To date, only weight loss fully reverses NASH pathology, but mixed peroxisome proliferator–activated receptor‐alpha/delta (PPAR‐α/δ) agonists show some efficacy. Seladelpar (MBX‐8025), a selective PPAR‐δ agonist, improves atherogenic dyslipidemia.

Characteristics of hepatic insulin‐sensitive nonalcoholic fatty liver disease

Fumika Shigiyama, Naoki Kumashiro, Yasuhiko Furukawa, Takashi Funayama, Kageumi Takeno, Noritaka Wakui, Takashi Ikehara, Hidenari Nagai, Hikari Taka, Tsutomu Fujimura, Hiroshi Uchino, Yoshifumi Tamura, Hirotaka Watada, Tetsuo Nemoto, Nobuyuki Shiraga, Yasukiyo Sumino, Takahisa Hirose – 29 July 2017 – Nonalcoholic fatty liver disease (NAFLD) plays a crucial role in type 2 diabetes and hepatocellular carcinoma. The major underlying pathogenesis is hepatic insulin resistance.

Outcome of liver transplantation in patients with prior bariatric surgery

Mohamed Safwan, Kelly M. Collins, Marwan S. Abouljoud, Reena Salgia – 28 July 2017 – Nonalcoholic fatty liver disease is becoming the leading cause of disease resulting in liver transplantation (LT). As a result of this trend, more LT candidates are presenting with prior history of bariatric surgery (BS). Over the last decade, 960 patients underwent LT at our institution; 11 (1.1%) had prior BS. The most common type of BS was Roux‐en‐Y gastric bypass (n = 9) with 1 sleeve gastrectomy and 1 jejunoileal bypass.

Subscribe to